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Overweight and obesity are associated with type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular
disease and cancer, but all fat is not equal, as storing excess lipid in subcutaneouswhite adipose tissue (SWAT)
ismoremetabolically favorable than in visceral fat. Here, we uncover a critical role formTORC2 in setting SWAT
lipid handling capacity. We find that subcutaneous white preadipocytes differentiating without the essential
mTORC2 subunitRictorupregulatemature adipocytemarkers but develop a striking lipid storagedefect result-
ing in smaller adipocytes, reduced tissue size, lipid re-distribution to visceral and brown fat, and sex-distinct
effects on systemic metabolic fitness. Mechanistically, mTORC2 promotes transcriptional upregulation of
select lipid metabolism genes controlled by PPARg and ChREBP, including genes that control lipid uptake,
synthesis, and degradation pathways as well as Akt2, which encodes a major mTORC2 substrate and insulin
effector. Further exploring this pathway may uncover new strategies to improve insulin sensitivity.
INTRODUCTION
White adipose tissue (WAT) stores energy and secretes endo-
crine factors that control metabolism (Guilherme et al., 2019;
Lee et al., 2017; Lefterova et al., 2014; Scherer, 2019). WAT ex-
pands in response to over-nutrition so that the excess calories
can be safely stored as triacylglycerol (TAG), preventing toxic
lipid accumulation in non-adipose tissues (Almandoz et al.,
2013; Snel et al., 2012; Unger et al., 2010). However, in over-
weight and obese individuals, white adipocytes become dysre-
gulated and contribute, through mechanisms incompletely
understood, to obesity-related comorbidities including type 2
diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), cardio-
vascular diseases (CVDs), and cancer (Van Gaal et al., 2006).
Thiazolidinediones (TZDs) are oral insulin sensitizing drugs
used to treat T2D. They act by stimulating PPARg, the master
transcriptional regulator of adipogenesis, to enhance insulin
sensitivity and promote glucose use and lipid synthesis and stor-
age (Hauner, 2002). Although TZDs are commonly prescribed,
serious side effects have limited their efficacy (Cariou et al.,
2012). Thus, a better understanding of PPARg regulation may
lead to improved therapies.
Importantly, not all WAT depots play equal roles in meta-
bolism. For example, the health risks of metabolic syndrome
and cardiovascular events for overweight patients with exces-
sive visceral WAT (VWAT) are higher than for individuals with
excess subcutaneousWAT (SWAT) (Ferrara et al., 2019; Lessard
and Tchernof, 2012; McLaughlin et al., 2011). An individual’s
body fat set point and ability to grow adipose tissue during devel-
opment and upon over-nutrition are also variable in the popula-
tion and between sexes (Fitzgerald et al., 2018; Tchoukalova
et al., 2010; Tramunt et al., 2020). Such complexities suggest
that anti-obesity therapies will likely have greater success
when personalized. Thus, understanding depot and sex differ-
ences in adipose tissue biology is also clinically relevant.
In mature white adipocytes, the mechanistic target of rapa-
mycin complex 2 (mTORC2) regulates glucose uptake and de
novo lipogenesis (DNL) in vivo in part through regulating the
carbohydrate response element binding protein (ChREBP) tran-
scription factor (Guo et al., 2019; Guri et al., 2017; Jung et al.,
2019; Tang et al., 2016). In humans, a positive correlation be-
tween DNL in SWAT and systemic insulin sensitivity has been
shown (Eissing et al., 2013; Roberts et al., 2009; Smith and
Kahn, 2016). Consistently, conditionally deleting Rictor in
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mice with Adiponectin-Cre, which targets all mature adipo-
cytes, causes insulin resistance (Tang et al., 2016; Yu et al.,
2019). The AKT kinases (AKT1, AKT2, and AKT3) are phosphor-
ylated by mTORC2 in their C-terminal hydrophobic motif (HM)
sites (Ser473, Ser474, and Ser472, respectively) (Hresko and
Mueckler, 2005; Sarbassov et al., 2005). However, global
downstream AKT signaling appears minimally affected in vivo
in Adiponectin-Cre;Rictor-knockout (KO) mice (RictorAdipoq-Cre)
despite the lack of AKT HM phosphorylation (Tang et al.,
2016). AKT2 is the major AKT isoform in adipocytes. Mutating
AKT2-S474 to alanine in vitro in 3T3L1 adipocytes also re-
vealed that HM phosphorylation is dispensable for insulin-stim-
ulated glucose uptake and mTORC1 activity (Beg et al., 2017),
while another study using AKT2-S474A mutant 3T3L1 adipo-
cytes showed that HM phosphorylation is required for maximal
AKT signaling to TSC2, PRAS40, FoxO1/3, and AS160 (Kearney
et al., 2019). Possible explanations for the observed differences
between models, which are not necessarily exclusive, are that
AKT signaling compensation occurs with prolonged Rictor
loss in vivo, but not equally across all AKT substrates or func-
tions; that individual AKT substrates inherently differ in their
mTORC2 dependency; and that AKT-independent mechanisms
contribute to WAT dysfunction. Moreover, mutating AKT2 S474
is not identical to deleting Rictor, as mTORC2 regulates other
AKT phosphorylation sites and AGC family kinases (Facchinetti
et al., 2008; Hiraoka et al., 2011; Ikenoue et al., 2008), and thus
variables in experimental strategy also likely contribute to some
of these differences. Nevertheless, previous studies focus
largely on mTORC2’s role in mature white adipocytes and
whether Rictor/mTORC2 is required for WAT development is
not known.
Here, we investigate the role of mTORC2 in subcutaneous fat
development using both in vitro and in vivo models. In both pri-
mary and immortalized cells, we find that Rictor/mTORC2 is not
required to induce PPARg during differentiation but that it is
required for the expression of specific PPARg target genes
that encode regulators of lipid uptake and storage. mTORC2
may not stimulate these PPARg genes through ChREBP but
rather in coordination with ChREBP to promote maximum lipid
storage capacity. To show physiological relevance, we also
deleted Rictor in vivo in precursor cells that give rise to
SWAT, but not to VWAT or brown adipose tissue (BAT). Consis-
tent with our in vitro findings, this impaired the expression of
select PPARg target genes that encode regulators of lipid
handling, in addition to attenuating expression of ChREBP/
SREBP1c target genes that control de novo lipid synthesis.
This resulted in reduced subcutaneous white adipocyte size,
reduced overall SWAT mass, and re-distribution of lipids to
the visceral and brown fat depots. Interestingly, this caused in-
sulin resistance in males. However, females were able to main-
tain normal insulin sensitivity despite Rictor loss causing a
similar but milder effect on SWAT mass and lipid re-distribu-
tion. Overall, these data suggest a model in which mTORC2
acts upstream of the adipogenic transcriptional machinery dur-
ing SWAT development to program lipid handling capacity. As
the ability to store lipid in SWAT is correlated with improved
metabolic health, these findings may have important implica-
tions for developing T2D treatments.
RESULTS
mTORC2 Promotes Lipid Filling during Subcutaneous
White Adipogenesis In Vitro
To investigate the role of mTORC2 in SWAT development, we
first generated a primary subcutaneous white adipocyte differ-
entiation model by isolating stromal vascular fraction (SVF) cells,
which contain preadipocytes, from the inguinal WAT depots of
UBC-CreERT2;RictorloxP/loxP mice and briefly treating them with
4-hydroxy tamoxifen (4-OHT) to induce Rictor deletion (Fig-
ure 1A). Following 4-OHT washout, primary Rictor-inducible
KO SVF cells (Rictor-iKOprimary preadipocytes hereafter) and
their isogenic vehicle-treated controls were differentiated
following a standard protocol (Zebisch et al., 2012). Staining of
differentiated primary adipocytes with oil red O (Figure 1B) or
by LipidTOX and Perilipin 1 (PLIN1) immunofluorescence (Fig-
ure 1C) indicates decreased lipid droplet accumulation in the
Rictor-iKOprimary cells. Quantification of the oil red O-stained lipid
droplets after isopropanol extraction indicates 20% less
neutral lipid in the Rictor-iKOprimary cells (Figure S1A). The total
cell number (Figure S1B) and percentage of PLIN1-positive cells
(Figure S1C) is unchanged by Rictor loss, suggesting a defect in
intracellular lipid accumulation. We also induced CreERT2 activity
in otherwise wild-type SVF cells (i.e., having no floxed Rictor al-
leles) to confirm that neither brief tamoxifen exposure nor tempo-
ral recombinase activity alone in the undifferentiated cells affects
oil red O staining, RICTOR level, or AKT phosphorylation upon
differentiation (Figures 1A, S1D, and S1E). These data suggest
that mTORC2 positively regulates subcutaneous white adipo-
cyte lipid accumulation.
We observed no difference in Pparg2, Cebpa, Cebpb,
and Cebpd mRNA expression during differentiation in Rictor-
iKOprimary cells (Figure 1D), and consistently, PPARg2 protein ex-
presses normally (Figure 1E). We did observe that the PPARg2
cofactor C/EBPa expresses at higher than normal protein level
following differentiation in Rictor-iKOprimary cells despite having
an unchangedmRNA expression profile (Figures 1D and 1E). Pri-
mary cells lacking Rictor have decreased AKT HM phosphoryla-
tion (S473 on AKT1, S474 on AKT2) and AKT turn motif phos-
phorylation (T450 on AKT1, T451 on AKT2) throughout
differentiation, confirming Rictor ablation (Figures 1E and 1F).
AKT1-T308/AKT2-T309 phosphorylation decreases by 50%
in Rictor-iKOprimary cells at day 0 (D0) and D2 of differentiation
but increases at D8 relative to controls (Figures 1F and 1G).
This is consistent with previous in vivo observations in adipo-
cytes that mTORC2 facilitates but is not essential for AKT-
T308 phosphorylation (Hung et al., 2014; Jung et al., 2019;
Tang et al., 2016). Interestingly, isoform-specific AKT1 and
AKT2 analysis shows a decrease in AKT2 mRNA induction dur-
ing differentiation, resulting in reduced AKT2 protein at D8 (Fig-
ures 1F and S1F). Transcriptional regulation of Akt2 was not
observed in Rictor-deleted mature adipocytes (Tang et al.,
2016). Nevertheless, the decrease in AKT2 level does not pre-
vent insulin (100 nM) from stimulating phosphorylation of AKT
substrates such as FoxO1 (T24), GSK3b (S9), or PRAS40
(T246) in the Rictor-deficient cells (Figures 1F and 1G). Collec-
tively, these data suggest that lipid accumulation during adipo-
genesis, but not differentiation, requires mTORC2.




We also immortalized UBC-CreERT2;RictorloxP/loxP SVF cells
(hereafter Rictor-iKOimmortal preadipocytes) to test whether
immortalization alters differentiation dynamics andmTORC2 de-
pendency. Like their primary cell counterparts, Rictor-iKOimmortal
preadipocytes have a lipid filling defect, exhibiting a 60%
decrease in oil red O staining after differentiation compared
with controls (Figure S1G). Similar to the Rictor-iKOprimary cells,
the D8 Rictor-iKOimmortal cells show reduced RICTOR and
AKT-S473/4 phosphorylation, slightly higher p-AKT-T308/9,
decreased AKT2 protein, and increased C/EBPa protein (Fig-
ure S1H). Notably, AKT1 mRNA and protein levels also increase
in the D8 Rictor-iKOimmortal cells, which is not detected in the
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Figure 1. mTORC2 Promotes Lipid Filling during Subcutaneous White Adipogenesis In Vitro
(A) Model of in vitro experimental strategy. 4-OHT, 4-hydroxytamoxifen; Cre-neg, Cre-negative cells; Cre-pos, Cre-positive cells.
(B) Oil red O (ORO) staining of differentiated (day 8) isogenic control and Rictor-iKO primary (Rictor-iKOprimary) cells.
(C) LipidTOX and Perilipin 1 (PLIN1) immunofluorescence staining of differentiated (day 8) control and Rictor-iKOprimary cells. Scale bar, 100 mm.
(D) Relative mRNA expression by RT-PCR of differentiation marker genes at the indicated differentiation days (n = 4; data represent mean ± SEM).
(E) Western blot of lysates from differentiated (day 8) cells. g1, PPARg1 isoform, g2, PPARg2.
(F) Western blot of the indicated total and phospho-proteins in lysates with or without 100 nM insulin (ins) stimulation at days 0, 2, and 8 of differentiation.
(G) Quantification of the indicated total and phosphorylated protein levels. Total AKT (asterisk) reflects AKT1 and AKT2 levels (n = 3; data represent mean ± SEM;
*p < 0.05 and **p < 0.01).
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Figure 2. mTORC2 Promotes Expression of Lipid-Handling Genes
(A) Upregulated (Rictor-suppressed) and downregulated (Rictor-required) genes at the indicated differentiation days (fold change > 1.4, adjusted p value <
0.05).
(B) Gene Ontology (GO) term enrichment analysis of day 8 Rictor-required adipogenic genes analyzed by the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID).
(C) KEGG pathway enrichment analysis of D8 Rictor-required adipogenic genes analyzed by DAVID.
(D) Genes requiring Rictor for induction classified by their published transcriptional activators. 1Compared with ChIP-Atlas database (Oki et al., 2018); 2compared
with the ChREBP targets listed in Iizuka (2017). *p < 0.05. Full gene names are listed in Table S5 and Figure S2A legend.
(legend continued on next page)




Rictor-iKOprimary cells, and this appears at least partly due to
increased Akt1 transcription (Figures S1H and S1I). There is
also a slight difference in PPARg2 induction in the immortalized
cells, which transcriptionally induces normally at D2, as in pri-
mary cells, but fails to maximally amplify thereafter (Figures
S1J and S1K). Nevertheless, Rictor-iKOimmortal preadipocytes
exhibit many of the same features as Rictor-iKOprimary preadipo-
cytes, with the observed differences likely resulting from the
immortalization procedure.
mTORC2 Promotes Expression of Lipid Handling Genes
To begin exploring how mTORC2 regulates lipid accumulation
during differentiation, we generated RNA sequencing (RNA-
seq) transcriptomes from the control and Rictor-iKOprimary SVF
cells in the precursor stage (D0), the terminal differentiation stage
(D2, when PPARg2 is induced), and the mature adipocyte stage
(D8) (Figure 1A). By first making pairwise comparisons between
the control and KO cells at each differentiation day examined, we
found that most of the differential gene expression occurs be-
tween D2 and D8 (Figure 2A). For example, we identified 141
genes significantly downregulated in Rictor-iKOprimary cells at
D8 compared with only 52 and 38 genes at D0 and D2, respec-
tively and 37, 76, and 78 upregulated genes at D0, D2, and D8
respectively (Figure 2A; Table S5). We classified the downregu-
lated genes as requiring Rictor for normal induction (Rictor-
required genes) and the upregulated genes as being suppressed
by Rictor (Rictor-suppressed genes) (Figure 2A). Gene Ontology
(GO) term and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway enrichment analysis for D0 and D2 Rictor-
required genes (those downregulated) reveals genes thought
to function in cell adhesion (n = 8) and extracellular matrix recep-
tor interaction pathways (n = 6) (Table S1). In contrast, the D8
Rictor-required genes are enriched for metabolic processes
especially lipid metabolism (n = 22) (Table S1). Among the Ric-
tor-suppressed genes is an over-representation of inflammation
pathway genes (Table S1). Notably, genes that suppress adipo-
genesis, such as Pref1 and Pdgfra, are not increased by Rictor
loss, consistent with Rictor-iKOprimary cells’ having a defect in
metabolic gene expression but not in differentiation. Thus,
mTORC2 is a positive regulator of lipid metabolic gene expres-
sion during adipocyte differentiation.
We also compared the D8 and D0 control transcriptomes to
identify adipogenic genes, which we defined as genes upregu-
lated >1.4 fold at a false discovery rate (FDR) < 0.05 in D8 versus
D0. This identified 825 adipogenic genes in the control primary
cells (Table S5). Among the D8 Rictor-required genes, 77 of
them (54.6%) are also adipogenic genes on the basis of this anal-
ysis (Table S5). GO analysis identified lipid metabolism genes as
being highly overrepresented among the D8 Rictor-required adi-
pogenic genes (Figure 2B). KEGG analysis further identified the
PPAR signaling pathway as the top scoring pathway among
the D8 Rictor-required genes (KEGG results on the basis of 10
of 77 genes) (Figure 2C). Notably, Rictor-required genes in the
PPAR signaling pathway encode regulators of both anabolic
and catabolic lipid metabolism such as fatty acid uptake, fatty
acid oxidation, DNL, and TAG synthesis (Figure S2A). By
comparing the D8 Rictor-required genes with a published data-
base of PPARg targets, we identified several additional Rictor-
required genes (41 of 141) as likely PPARg targets (Figure 2D).
In addition, 6 and 20 of Rictor-required genes are also classified
as ChREBP and/or SREBP1 targets, respectively, on the basis of
published data (Oki et al., 2018; Ortega-Prieto and Postic, 2019)
(Figure 2D). The complete gene lists for each category in this
section are available in Table S5.
For several of the Rictor-required genes identified by RNA-
seq, we developed RT-PCR assays to confirm their D8 expres-
sion differences in primary cells (Figure 2E). We focused on
genes that regulate lipid metabolism, including previously re-
ported PPARg target genes (Scd1, Dgat1, Glut4, Cd36, Lpl,
Fabp4, Hsl, and Mcad), DNL genes (Acaca, Fasn, and Scd1),
and as controls, Rictor-independent adipogenic genes (Plin1
andAdipoq). As predicted from theRNA-seq data, genes encod-
ing regulators of several lipid anabolic pathways, such as fatty
acid and TAG synthesis (Acaca, Fasn, Scd1, Dgat1, and Dgat2)
and glucose and fatty acid uptake (Glut4, Cd36, Lpl, and
Fabp4) are decreased in D8 Rictor-iKOprimary cells (Figure 2E).
We also confirmed attenuation of genes that encode regulators
of lipid catabolic processes such as lipolysis (Hsl) and beta-
oxidation (Mcad) in Rictor-iKOprimary cells (Figure 2E). We further
confirmed decreased CD36, FABP4, ACC, FASN, and SCD1
protein expression by western blot (Figure 2F). In contrast, the
PPARg targets Plin1 and Adipoq are unaffected by Rictor loss
(Figure 2E), which is also consistent with normal PLIN1-positive
staining in the D8 adipocytes (Figures 1C and S1C). Importantly,
the control CreERT2 cells (Figure 1A) show no defects in Acaca,
Fasn, Scd1, Cd36, Lpl, Fabp4, or Glut4 expression (Figure S2B).
We confirmed that decreased expression of the PPARg targets
Cd36 and Fabp4 requires Rictor deletion prior to differentiation,
as deleting Rictor after differentiation did not attenuate their
expression despite ablating AKT-S473 phosphorylation (Figures
S2C and S2D). In contrast, DNL genes (Acaca and Fasn) require
Rictor both during differentiation and in mature adipocytes (Fig-
ure S2D) consistent with our previous in vivo findings (Tang et al.,
2016). Thus, without Rictor, differentiating SWAT preadipocytes
cannot establish their normal lipid metabolic gene expression
program, which includes regulators of lipid synthesis, uptake,
breakdown, and oxidation pathways.
To confirm that the observed gene expression differences
reflect metabolic changes, we performed functional assays.
Using 14C-glucose, we show that lipid synthesis increases 65-
fold from D0 to D8 in control cells and confirmed that D8
Rictor-iKOprimary cells have a 92% reduction in de novo lipid syn-
thesis, with the D0 cells also showing a slight decrease (Fig-
ure S2E). Consistent with reduced Glut4 expression, we also
measured 25% and 35% decreases in insulin-stimulated 3H-2-
DG glucose uptake at D0 and D8, respectively (Figure S2F).
(E) Relative mRNA expression by RT-PCR of the indicated genes in day 8 control and Rictor-iKOprimary cells (nR 3; data represent mean ± SEM; *p < 0.05, **p <
0.01, and ***p < 0.001).
(F) Western blot of the indicated total proteins in lysates from undifferentiated (D0) and differentiated (D8) control and Rictor-iKOprimary cells. g1, PPARg1 isoform;
g2, PPARg2. Numbers at the left are protein sizes in kilodaltons.




However, non-insulin-stimulated glycolysis and glycolytic ca-
pacity measured on a Seahorse Extracellular Flux Analyzer ex-
hibited higher and normal capacity, respectively, on the basis
of extracellular acidification rate (Figure S2G), which is
consistent with RNA-seq data showing normal glycolysis gene
expression in Rictor-iKOprimary cells (Table S5; Figure S2A). Us-
ing BODIPY as a probe to measure lipid uptake, we also
measured 25% and 35% decreases in lipid uptake after 10
and 30 min of labeling, respectively, in Rictor-iKOprimary cells
(Figure S2H). These data are consistent with a model in which
mTORC2 sets the general lipid handling capacity of SWAT dur-
ing adipogenesis.
Specific PPARg Targets RequireRictor for Full Induction
To further explore the connection between mTORC2 and
PPARg, we expressed a PPARg activity reporter construct that
contains three PPRE elements in the luciferase promoter (Kim
et al., 1998) in control and Rictor-iKOimmortal cells and quantified
reporter gene activity at D2 of differentiation. As expected, re-
porter activity increases 2-fold when the activity at D2 is
compared with that in undifferentiated cells (D0) (Figure S3A).
Reporter activity decreases by 53% when Rictor is deleted (Fig-
ure S3A), and while supplementing the PPARg agonist rosiglita-
zone enhances reporter activity 1.8-fold in control cells, it has no
effect in the Rictor-iKOimmortal cells (Figure S3A). Similarly, over-
expressing recombinant HA-PPARg2 enhances reporter activity
2-fold over baseline in D2 control cells, and this is reduced by
58% in the Rictor-iKOimmortal cells despite recombinant HA-
PPARg2 expressing at similar levels in the control and KO cells
(Figures S3A and S3B). Moreover, overexpressing HA-PPARg2
does not rescue lipid droplet accumulation in Rictor-deficient
cells upon differentiation (Figure S3C). It also fails to restore
expression of Cd36, Lpl, Fabp4, Acaca, Fasn, or Scd1 (Fig-
ure S3D) or ATP citrate lyase (ACLY), ACC, or FASN protein
expression (Figure S3E), although lipid content and Cd36
expression do show minor increases relative to Rictor-deficient
cells expressing the empty vector control. We also tested
whether supplementing rosiglitazone during the full differentia-
tion assay would improve the Rictor-KO phenotype. Rosiglita-
zone does increase oil red O staining and target gene expression
in both control and Rictor-iKOimmortal cells, but lipid accumula-
tion and gene expression remain significantly attenuated in
Rictor-iKOimmortal cells relative to control (Figures S3F–S3H).
Overall, these data are consistent with Rictor loss impairing
PPARg activity.
Next, we used chromatin immunoprecipitation (ChIP) assay to
examine endogenous PPARg target gene promoters in primary
cells for both PPARg binding to PPRE elements and for histone
H3K9 acetylation, which is associated with PPARg target gene
activity (Lefterova et al., 2008; Salma et al., 2004; Steger et al.,
2010; Wang et al., 2019). We examined the PPRE regions in Ric-
tor-dependent (Cd36 and Fabp4) and a Rictor-independent
(Pkm2) PPARg target (Figures S4A and S4B; Table S4). At differ-
entiation D2, PPARg-PPRE binding is unchanged at the
promoters of Cd36, Fabp4, and Pkm2 when Rictor is absent;
however, at D8, PPARg binding at the Cd36 and Fabp4 PPREs
decreases by 40% and 33%, respectively, in the absence ofRic-
tor (Figure 3A). In contrast, but consistent with our gene expres-
sion analysis, PPARg binding to the Pkm2 promoter (Panasyuk
et al., 2012) is unaffected byRictor loss (Figure 3A). Deleting Ric-
tor also decreasedH3K9ac by 40%and 44%, respectively, in the
PPREs of Cd36 and Fabp4 at D2, preceding measurable loss of
PPARg binding (Figure 3B). H3K9ac further decreases at both
promoters by 73% and 80%, respectively, at D8 while remaining
unaffected in the Pkm2 PPRE throughout differentiation (Fig-
ure 3B). Similar results were obtained using theRictor-iKOimmortal
system; for example, PPARg binding to the Fabp4-PPRE de-
creases in Rictor-iKOimmortal cells, although the defect occurs
2 days earlier in the immortalized cells than in the primary cells
(Figure S4C). This is consistent with the immortalized cells but
not the primary cells, showing greater dependency on Rictor
for PPARg amplification (Figures S1J and S1K). Total histone
H3 levels and global H3K9 acetylation appear unaffected by Ric-
tor loss (Figure S4D). These data are consistent with specific
PPARg targets requiring Rictor for full induction during
differentiation.
Neither ChREBPb nor SREBP1n Overexpression Is
Sufficient to Rescue PPARg Target Genes
In mature adipocytes, mTORC2 positively regulates expression
of the transcription factor ChREBPb and its target genes in the
DNL pathway (e.g., Acly, Acc, Fasn) (Tang et al., 2016).
ChREBPb has also been shown to regulate PPARg expression
and activity in 3T3L1 cells during adipogenesis (Witte et al.,
2015). Therefore, we asked whether overexpressing recombi-
nant ChREBPa or ChREBPb in Rictor-iKOimmortal cells could
rescue lipid accumulation and PPARg gene expression. In the
control cells, overexpressing recombinant ChREBPb increases
lipid amount by 20%determined by oil red O staining (Figure 4A);
however, lipid accumulation is unaffected in Rictor-iKO cells
overexpressing ChREBPa or ChREBPb (Figure 4A). Notably, ex-
pressing ChREBPb partially restored the mRNA and protein
expression of ACLY, ACC, and FASN (Figures 4B and 4C), but
it had no impact on the PPARg target genes Cd36, Lpl, Fabp4,
Dgat1, and Dgat2 (Figure 4C). Expressing ChREBPa had no ef-
fect on PPARg target genes and minimal effects on DNL gene
expression (Figures 4A–4C). The SREBP1 lipogenic transcription
factor shares targets with ChREBP, and its activity is positively
linked to mTORC2 in the liver (Hagiwara et al., 2012; Yuan
et al., 2012). Interestingly, however, we observe an increase in
the level of nuclear SREBP1 (SREBP1n) in both Rictor-iKOprimary
and Rictor-iKOimmortal cells (Figures 4D and 4F), suggesting
increased SREBP1 processing. Consistent with this, the gene
encoding the SREBP-processing inhibitor INSIG1 is a Rictor-
required gene (Figure 2D; Table S5). Moreover, overexpressing
the transcriptionally active SREBP1n cleavage product in Ric-
tor-iKOimmortal cells had little effect on PPARg target gene
expression and failed to restore lipid droplet formation (Figures
4E–4G). Thus, neither ChREBPa/b nor SREBP1n overexpression
is sufficient to restore defects in lipid metabolic gene expression
when cells differentiate in the absence of Rictor.
In contrast to our findings in this study, previous work using a
brown preadipocyte differentiation model showed that Rictor is
required for PPARg2 induction (Calejman et al., 2020; Hung
et al., 2014), suggesting that brown and white preadipocyte dif-
ferentiation may have different mTORC2 requirements in vitro.




Consistent with this notion, we recently showed that overex-
pressing ACLY or ACLY-S455D partially and completely rescues
Rictor loss in the brown preadipocyte model (Calejman et al.,
2020); however, in Rictor-deficient subcutaneous white preadi-
pocytes, stably overexpressing recombinant ACLY, ACLY-
S455D, or ACLY-S455E does not rescue lipid accumulation
(Figure S4E), Pparg2, Cd36, or Fabp4 gene expression (Fig-
ure S4F), or ACC protein levels during differentiation
(Figure S4G). In fact, overexpressing ACLY enhances the sup-
pressive effect ofRictor loss on gene expression in thewhite pre-
adipocyte model (Figure S4F). This is consistent with these
models of brown and subcutaneous white adipogenesis having
different mTORC2 requirements.
AKT1-S473D Restores PPARg Target Gene Expression
Next, we asked whether rescuing AKT HM phosphorylation
could restore PPARg target gene expression by generating Ric-
tor-iKOimmortal cells expressing recombinant HA-AKT1-S473D or
HA-AKT2-S474D phospho-mimetics or their HA-AKT1 and HA-
AKT2 wild-type and HA-AKT1-S473A phospho-deficient
controls. Only HA-AKT1-S473D restores lipid accumulation in
differentiating Rictor-iKOimmortal cells (Figures 5A and 5B). West-
ern blot confirms expression of each recombinant AKT construct
(Figure 5C). Overexpressing HA-AKT1-S473D also increases
Chrebpb, Acaca, Pparg2, Fabp4, and Cd36 expression as well
as ACC protein expression in Rictor-iKOimmortal cells (Figures
5C and 5D). HA-S474D-AKT2 and to a lesser extent HA-AKT2
wild-type also increases Chrebpb expression consistent with a
recent study linking AKT2 and ChREBP-dependent DNL in
brown fat (Figure 5D) (Sanchez-Gurmaches et al., 2019) and sug-
gesting that AKT1 and AKT2 may cooperate or compensate for
each other in ChREBP regulation. Thus, restoring AKT HM phos-
phorylation is sufficient to rescue Rictor-dependent lipid meta-
bolic gene expression.
SWAT Development Requires mTORC2 In Vivo
To examine the physiological relevance of these findings, we
generated Prx1-Cre;Rictorfl/fl mice (RictorPrx1-Cre) in which Rictor
is deleted in vivo in a precursor cell population that gives rise to
posterior SWAT but not to VWAT or BAT (Krueger et al., 2014;
Sanchez-Gurmaches et al., 2015). RictorPrx1-Cre mice weigh
significantly less than controls starting at 6 and 12 weeks of
age for females and males, respectively (Figure 6A). Food intake
is equivalent between groups (Figure S5A). In both sexes, the
SWAT weighs significantly less in RictorPrx1-Cre mice (65% less
in males and 57% less in females) (Figures 6B and 6C). H&E
staining and imaging of the whole SWAT depot show reduced
adipocyte size in RictorPrx1-Cre mice (Figures 6D and 6E). Recip-
rocally, VWAT and BATmasses in themaleRictorPrx1-Cremice in-
crease by 60% and 35%, respectively, as a result of adipocyte
hypertrophy (Figures 6B–6E). On the other hand, VWATmass in-
creases by only 40% in the femaleRictorPrx1-Cremice (Figures 6B
and 6C), because of milder cell hypertrophy (Figures 6D and 6E),
but there is no significant difference in female BATmass (Figures
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Figure 3. Specific PPARg Targets Require Rictor for Full Induction
(A) PPARg/PPAR-responsive element (PPRE) interaction identified by chromatin immunoprecipitation (ChIP) atCd36, Fabp4, and Pkm2 promoters in control and
Rictor-iKOprimary cells (n = 3 for PPARg ChIP, n = 3 for IgG ChIP; data represent mean ± SEM; **p < 0.01). ChIP with IgG were used as negative controls.
(B) H3K9 acetylation (H3K9ac) by ChIP analysis at Cd36, Fabp4, and Pkm2 promoters in control and Rictor-iKOprimary cells (n = 3 for PPARg ChIP, n = 3 for IgG
ChIP; data represent mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001). ChIP with IgG were used as negative controls.
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Figure 4. Overexpressing ChREBPb or SREBP1n Does Not Rescue Rictor Loss
(A) Oil red O (ORO) staining of differentiated control (EtOH) and Rictor-iKOimmortal (4-OHT) cells expressing empty vector (Vec), ChREBPa, or ChREBPb. The
number below represents quantification (quant) of oil red O after isopropanol extraction (scale bar, 50 mm; data represent mean ± SEM).
(B) Western blot of lysates corresponding to (A).
(C) Relative mRNA expression by RT-PCR of the indicated genes corresponding to (A) (n = 3; data represent mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001).
a–c denote comparison of overexpressing cells to vector-containing cells: a, p < 0.05; b, p < 0.01; c, p < 0.001.
(D) Western blot of lysates from differentiated (D8) control and Rictor-iKOprimary cells. fl, full-length SREBP1; n, processed nuclear SREBP1 product.
(E) Oil red O (ORO) staining of differentiated control and Rictor-iKOimmortal cells expressing empty vector (Vec) or SREBP1n. The number below represents
quantification (quant) of oil red O after isopropanol extraction (data represent mean ± SEM).
(F) Western blot of lysates from differentiated control and Rictor-iKOimmortal cells corresponding to (E). S.E., shorter exposure.
(G) Relative mRNA expression by RT-PCR of indicated genes in control and Rictor-iKOimmortal cells corresponding to (E) (n = 3; data represent mean ± SEM; *p <
0.05, **p < 0.01, and ***p < 0.001). a–c denote comparison of overexpressing cells to vector-containing cells: a, p < 0.05; b, p < 0.01; c, p < 0.001.


















































































































































































































































































































Figure 5. AKT1-S473D Is Sufficient to Rescue Lipid Accumulation Defect in Rictor-KO Cells
(A) Oil red O (ORO) staining of differentiated control (EtOH) and Rictor-iKOimmortal (4-OHT) cells expressing empty vector, HA-AKT1, HA-AKT1-S473D, HA-AKT1-
S473A, HA-AKT2, or HA-AKT2-S474D.
(B) Quantification of oil red O from (A) after isopropanol extraction (scale bar, 50 mm; data represent mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001).
(C)Western blot of lysates fromdifferentiated control (EtOH) andRictor-iKOimmortal (4-OHT) cells expressing empty vector, HA-tagged AKT1, AKT1-S473D, AKT1-
S473A, AKT2, or AKT2-S474D.
(D) Relative mRNA expression by RT-PCR of the indicated genes corresponding to (A) (n = 3; data represent mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001).
a–c denote comparison of overexpressing cells to vector-containing cells: a, p < 0.05; b, p < 0.01; c, p < 0.001.
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Figure 6. Subcutaneous White Adipose Tissue Growth Requires mTORC2 In Vivo
(A) Growth curves of male (M) and female (F) control and RictorPrx1-Cre mice (n = 10–14; data represent mean ± SEM; t test; *p < 0.05).
(B) Tissueweight relative to bodyweight of subcutaneouswhite adipose tissue (SWAT), visceral white adipose tissue (VWAT), and brown adipose tissue (BAT) (n =
8–10; data represent mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001).
(C) Representative images of the indicated fat depots from 8-week-old male control and RictorPrx1-Cre mice.
(D) H&E stains corresponding to the tissues in (C) for both male and female mice (scale bar, 100 mm).
(E) Individual adipocyte cell size distribution in each indicated depot (n = 4mice; >1,000 and 500–1,000 individual adipocytes measured from SWAT and VWAT of
each mouse, respectively; data represent mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001).
(F) Representative western blot of lysates from SWAT, VWAT, and BAT of 8-week-old male control and RictorPrx1-Cre mice.




6B and 6C). We determined that reduced tissue mass is mainly a
result of smaller cell size by calculating total depot cellularity
(Parlee et al., 2014), which reveals a linear relationship between
tissue weight and average adipocyte volume (r2 = 0.97 in male
SAT and r2 = 0.80 in female SAT) suggesting no significant differ-
ence in cellularity (Figure S5B). Moreover, adipocyte precursor
cell (APC) number is unchanged between the SWAT of Ric-
torPrx1-Cre mice and controls (Figure S5C) consistent with the
SWAT partial-lipodystrophy phenotype originating from a lipid
accumulation defect during adipogenesis. Western blotting con-
firms that RictorPrx1-Cre mice lack RICTOR and p-AKT-S473 in
posterior SWAT, but not in VWAT or BAT (Figure 6F). Neither
male nor female RictorPrx1-Cre mice have enlarged livers (Fig-
ure S5D) or evidence of hepatic steatosis on the basis of direct
TAG measurement (Figure S5E). Analysis of neonates indicates
that SWAT lipodystrophy occurs as early as postpartum D7
(P7), at which point the SWAT weighs 40% less and contains
smaller adipocytes (Figures S5F–S5H). This is in stark contrast
to deleting Rictor in mature adipocytes (e.g., with Adiponectin-
Cre), which does not affect adipose tissue mass or adipocyte
size through 20 weeks of age on standard chow (Tang et al.,
2016). These data are consistent with Rictor’s also being
required for SWAT development in vivo and further reveals a
sex difference in how adipose tissue lipids are redistributed
following Rictor loss.
Prx1-Cre-expressing precursors also give rise to some bone
marrow adipocytes as well as osteoblasts and chondrocytes
(Krueger et al., 2014; Logan et al., 2002). Consequently,
computed tomographic (CT) scanning shows that the femur
and tibia of male RictorPrx1-Cre mice are 10% and 5% shorter,
respectively, correlating with thinner cortical and trabecular
bone, which is more prominent in males (Figure S5I; Table S2)
(Chen et al., 2015; Liu et al., 2016; Sun et al., 2016). Reduced
bone length may explain why the quadriceps also weighs slightly
less in RictorPrx1-Cre mice despite the muscle’s having normal
morphology and RICTOR expression (Figures S5J–S5L). Ric-
torPrx1-Cre male mice also have less bone marrow volume (MV)
in the proximal region and a trending decrease in marrow adi-
pose tissue (MAT) especially in females, as shown by osmium
staining combined with CT scanning (Table S3) (Scheller et al.,
2015). Gene expression analysis confirms reduced Rictor
mRNA expression but normal Pparg2 expression in the marrow
adipocytes of both male and female RictorPrx1-Cre mice (Fig-
ure S5M). These data are consistent with previous studies
showing that Prx1-Cre also targets bone marrow mesenchyme
(Krueger et al., 2014) and MAT (Sun et al., 2016).
Male Rictorprx1-Cre Mice Become Insulin Resistant
We next asked if SWAT dysfunction due to Rictor loss causes in-
sulin resistance. Interestingly, 8-week-old male RictorPrx1-Cre
mice develop insulin intolerance, as indicated by a 30% increase
in glucose AUC relative to controls (Figure S6A). This correlates
with a trending increase in serum insulin level in males (Fig-
ure S6E). This is not observed in females (Figure S6B), and
neither sex shows defects in glucose tolerance (Figures S6C
and S6D). Adiponectin, leptin, and non-esterified fatty acids (NE-
FAs) are unchanged in RictorPrx1-Cre male mice fed ad libitum
(Figure S6E). The propensity for male RictorPrx1-Cre to develop in-
sulin resistance is consistent with their greater accumulation of
visceral fat.
Rictor Is Required In Vivo during SWAT Development for
Lipid Metabolic Gene Expression
Similar to what we observed in vitro (i.e., in the D8 primary cells
that were differentiated in the absence of Rictor), the SWAT of
RictorPrx1-Cre mice expresses PPARg and C/EBPa in vivo as
well as insulin receptor beta (IRb; which is elevated over control)
(Figure 7A). Also, similar to the in vitro models, the SWAT from
Rictorprx1-Cremice has reduced AKT2mRNA and protein expres-
sion (Figures 7A and S7A). In vivo, reduced AKT2 expression cor-
relates with reduced p-AKT-T308, which is consistent with
AKT2’s being the major AKT isoform in mature adipocytes.
Interestingly, despite reduced p-AKT-T308, p-AS160-T642, p-
GSK3b-S9, and p-FoxO1-T24 remain intact; however, p-
PRAS40-T246 is reduced (Figure 7A). PRAS40 phosphorylation
relieves its negative effect on mTORC1, and consistently, p-
S6K1-T389 (a direct mTORC1 substrate) is also reduced (Fig-
ure 7A). We did not observe this effect in vitro (Figures 1F and
S7B) or in vivo when Rictor is deleted in mature adipocytes
with Adiponectin-Cre (Tang et al., 2016), suggesting the
mTORC1-S6K1 signaling defect is a secondary effect caused
by reduced AKT2 induction during differentiation.
We next asked whether SWAT lipid-handling genes require
Rictor during development for their expression in vivo. This is
indeed the case for all of the Rictor-required anabolic and cata-
bolic lipid metabolism genes as well as their products that we
examined and that were previously identified by primary cell
RNA-seq (Figures 7A and 7B). Adiponectin, however, is reduced
in expression in vivo but not in the primary cell model (Figure 7B).
This is consistent with previous observations showing that adi-
ponectin levels may be sensitive to prolonged adipocyte Rictor
loss in vivo (Cybulski et al., 2009; Tang et al., 2016). Notably,
SWAT primary SVF preadipocytes isolated from Rictorprx1-Cre
mice and differentiated in vitro also show reduced lipid accumu-
lation (Figure S7C), decreased lipogenic and TAG synthesis gene
and/or protein expression (Figures S7D and S7E), and
decreased AKT2 expression (Figures S7D and S7E) after
differentiation. Moreover,AdiponectinmRNA expression is unaf-
fected in primary RictorPrx1-Cre preadipocytes that are differenti-
ated (Figure S7E), consistent with downregulation ofAdiponectin
mRNA occurring secondary toRictor loss. Consistent with previ-
ous data, Rictor-deficient SWAT also has defective insulin-stim-
ulated glucose uptake and increased basal lipolysis (Figures S7F
and S7G). These data confirm the physiological relevance of our
in vitro findings and the role of mTORC2 in establishing the lipid
handling capacity of SWAT.
In our previous study of RictorAdipoq-Cre mice, in which Rictor
was deleted in mature adipocytes rather than in precursors as
in this study, the expression of the PPARg target genes Cd36,
Lpl, and Fabp4 were unchanged between the control and Ric-
tor-deficient SWAT depots when mice were eating standard
chow ad libitum (Tang et al., 2016). Reasoning that the difference
could be explained by SWAT development’s placing a greater
demand on mTORC2-regulated PPARg activity, we wondered
whether challenging RictorAdipoq-Cre mice to store more lipid in
SWAT would reveal the PPARg gene expression defects. To




this end, we re-examined PPARg gene expression in
RictorAdipoq-Cre mice that were refed following a fast or given a
high-fat diet (HFD). Indeed, challenging RictorAdipoq-Cre mice
with a prolonged fast followed by 6 h of refeeding resulted in
36%, 50%, and 60% reductions inCd36, Lpl, andDgat2 expres-
sion, respectively, corresponding to a 33% reduction in tissue
mass relative to controls (Figures 7C and 7D). Similarly, placing
RictorAdipoq-Cre on HFD for 12 weeks failed to increase Cd36,
Lpl, and Fabp4 expression in the Rictor-KO fat (Figure 7E),
consistent with reduced adipose tissue lipid accretion and over-
all smaller adipocytes (Figure 7F) (Tang et al., 2016). We
conclude that mTORC2 is required to maximally stimulate
expression of PPARg-dependent lipid storage genes in subcu-
taneous white adipocytes when they are challenged with




































































































































































Figure 7. Rictor Regulates Expression of Lipid-Handling Genes during SWAT Growth
(A) Western blot of lysates from the subcutaneous white adipose tissue (SWAT) of 8-week-old control and RictorPrx1-Cre mice.
(B) Relative mRNA expression by RT-PCR of indicated genes from SWAT of 8-week-old control and RictorPrx1-Cremice (n = 6–8; data represent mean ±SEM; *p <
0.05, **p < 0.01, and ***p < 0.001).
(C) Tissue weight of SWAT of 8-week-old control and RictorAdipoq-Cre mice refed for 6 h following 24 h fasting (n = 8; data represent mean ± SEM; ***p < 0.001).
(D) Relative mRNA expression by RT-PCR of indicated genes from SWAT of 8-week-old control andRictorAdipoq-Cremice refed for 6 h following 24 h fasting (n = 8;
data represent mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001).
(E) Relative mRNA expression by RT-PCR of indicated genes from SWAT of control and RictorAdipoq-Cre mice after 12 week HFD or standard chow (SC) feeding
(n = 7 or 8; data represent mean ± SEM; *p < 0.05 and **p < 0.01; a, p < 0.05 when HFD samples were compared with SC samples).
(F) H&E stains of SWAT from control and RictorAdipoq-Cre mice after 12 week HFD or chow (SC) feeding (scale bar, 100 mm).




physiological states that draw high demand on lipid storage
pathways, such as tissue development, refeeding after a fast,
and chronic obesogenic diets.
DISCUSSION
In this study, we investigate the role of mTORC2 in SWAT devel-
opment. Our findings support a model in which differentiating
subcutaneous white adipocytes require Rictor/mTORC2 to
establish maximum lipid handling capacity during development.
This is mediated in part by positively regulating expression of
specific PPARg genes that encode regulators of lipid storage.
One possibility is that mTORC2 regulates PPARg’s ability to
identify and/or remain associated with specific targets through
a factor that cooperates with PPARg (such as a protein ormetab-
olite), by acting downstream (e.g., by regulating the chromatin
state), or through direct regulation, although possibly arguing
against the latter is the observation that only select PPARg tar-
gets are mTORC2 dependent. Regardless, rescue experts sug-
gest mTORC2 acts on these PPARg genes at least in part
through AKT signaling. Moreover, mTORC2 is required for
maximum PPARg target gene expression in mature subcutane-
ous white adipocytes, particularly during dietary challenges that
promote rapid lipid storage and adipose tissue growth, such as
consuming an HFD. TZDs, which are drugs used to treat T2D,
work by binding and stimulating PPARg, but they have negative
side effects, including potential heart failure (Cariou et al., 2012).
Because mTORC2 appears to promote only a subset of PPARg
activities, our study may help identify alternative mechanisms to
stimulate safe lipid storage and insulin sensitivity.
Incontrast toourpresent findings inwhitepreadipocytedifferen-
tiation, Rictor is required for PPARg mRNA induction in a brown
preadipocyte differentiation model, and therefore, Rictor-deficient
brown preadipocytes are completely incapable of differentiating
and synthesizing lipid droplets when subjected to standard
in vitro differentiation assays. In brown preadipocytes, this defect
is linked to a deficiency in ACLY phosphorylation (S455) and
acetyl-coAproduction.Thisphenotype ispartially rescuedbyover-
expressing recombinantACLYandcompletely rescuedbyoverex-
pressing the phospho-mimetic construct ACLY-S455D (Calejman
et al., 2020). A recent study using a non-adipocyte model (primary
bovine mammary epithelial cells) also showed blocked PPARg2
expression when Rictor was knocked down by short hairpin RNA
(shRNA) (Guo et al., 2019). Consistent with the brown and white
preadipocyte differentiation models showing different require-
ments for mTORC2 (i.e., Rictor is not required for PPARg2 mRNA
induction here), overexpressing ACLY-S455D did not rescue
gene expression and lipid accumulation defects in theRictor-defi-
cient subcutaneous white preadipocytes in this study. One expla-
nation for why these brown and white adipocyte differentiation
models differ is that they are different cell types derived from the
natural precursor cell population in their respective depots (i.e., in-
terscapular BAT and inguinal WAT). Alternatively, the brown prea-
dipocytes are immortalized using the SV40-Large T antigen proto-
col (Fasshauer et al., 2000), which could change the metabolic
requirements for PPARg induction. Determining how mTORC2
signaling regulates metabolism and gene expression across
different cell types is an important ongoing area of research.
How might mTORC2 regulate PPARg activity? One possibility
is that a PPARg post-translational modification(s), such as phos-
phorylation, acetylation, SUMOylation, or O-GlcNAcylation,
could be sensitive to mTORC2 signaling (Brunmeir and Xu
2018; Floyd and Stephens, 2004; Jennewein et al., 2008; Ji
et al., 2012; Ohshima et al., 2004; Pascual et al., 2005). For
example, phosphorylation of PPARg increases or decreases its
activity depending on the sites and the upstream regulators
(Choi et al., 2014, 2010; Compe et al., 2005; Helenius et al.,
2009; Hu et al., 1996; Iankova et al., 2006; Adams et al., 1997).
Acetylation of PPARg, on the other hand, has been shown to
positively regulate lipid synthesis (Tian et al., 2014). Another pos-
sibility is that mTORC2 regulates the ability of PPARg to bind
certain co-factors (Miard and Fajas, 2005), which could include
histone acetyltransferases (HATs) or histone deacetylases
(HDACs) (Miard and Fajas, 2005). mTORC2 could also regulate
PPARg’s ability to bind certain targets by affecting the chromatin
landscape or chromatin remodeling factors, evidenced by
decreased H3K9ac in Rictor-KO PPREs shown here (Lefterova
et al., 2010; Zhang et al., 2012). Combining global gene expres-
sion analysis with chromatin modification profiling, especially
in vivo, will be important to differentiate among these possibilities
(Roh et al., 2017). The detailed mechanism of howmTORC2 reg-
ulates PPARg activity is still under investigation.
Another interesting finding in our study is that male and female
mice respond differently to Prx1-Cre-mediated Rictor deletion
with respect to fat re-distribution and insulin sensitivity. For
example, only male RictorPrx1-Cre mice develop insulin resis-
tance. Interestingly, although RictorAdipoq-Cre mice do not exhibit
lipodystrophy, they are also insulin resistant, and this is more
pronounced in male mice (Tang et al., 2016; Yu et al., 2019).
Thus, adipose mTORC2 may play a greater role in controlling
systemic insulin sensitivity in males than in females, and the
SWAT may be particularly important to this phenomenon. The
mechanism controlling this is currently unknown. However,
these observations add to the growing appreciation for sex dif-
ferences in adipose tissuemetabolic regulation. For example, fe-
male Adiponectin-Cre;Aclyfloxed mice were recently reported to
have a more severe metabolic phenotype than their male KO
counterparts (Fernandez et al., 2019). Understanding sex differ-
ences in adipose tissue metabolism is an exciting ongoing
research area.
One limitation of our study is that Prx1-Cre targets other cell
lineages in addition to SWAT, including some bone lineages
and marrow adipocytes. Importantly for this study, however,
Prx1-Cre does not target precursors of brown fat or visceral
white fat (Krueger et al., 2014; Sanchez-Gurmaches et al.,
2015). Our use of three different in vitro differentiation models
that exhibit overlapping phenotypes with one another and the
in vivo model, including primary SVF preadipocytes derived
from the RictorPrx1-Cre mice, greatly strengthens the ability to
distinguish the mTORC2 functions that are specific to SWAT
development. Nevertheless, effects caused by Rictor loss in
non-adipose tissue cells cannot be ruled out in the in vivomodel.
Unfortunately, there is also no reciprocal Cre driver that is as
robust at targeting only VWAT precursors. Therefore, we cannot
make conclusions about how mTORC2 might function in VWAT
development. Although our AKT rescue experiments support a




model in whichRictor is acting throughmTORC2 to promote lipid
gene expression, we cannot rule on the possibility that Rictor
might also havemTOR-independent functions in adipose tissues
(Gao et al., 2010; Hagan et al., 2008). This aspect of Rictor
biology remains poorly understood.
Overall, our study reveals previously unknown mTORC2 func-
tions in regulating SWAT growth, adipose tissue gene expres-
sion, and sex-dependent metabolic homeostasis. These conclu-
sions may have important implications for understanding and
treating T2D and other obesity-related metabolic diseases.
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Phospho-S473-AKT Cell Signaling Technology Cat# 4058; RRID: AB_331168
Phospho-T450-AKT Cell Signaling Technology Cat# 9267; RRID: AB_823676
Phospho-T308-AKT Cell Signaling Technology Cat# 4056; RRID: AB_331163
Phospho-S473-AKT1 Cell Signaling Technology Cat# 9018; RRID: AB_2629283
Phospho-S474-AKT2 Cell Signaling Technology Cat# 8599; RRID: AB_2630347
AKT1 Cell Signaling Technology Cat# 2938; RRID: AB_915788
AKT2 Cell Signaling Technology Cat# 3063; RRID: AB_2225186
AKT Cell Signaling Technology Cat# 9272; RRID: AB_329827
Phospho-T24-FoxO1 Cell Signaling Technology Cat# 9464; RRID: AB_329842
FoxO1 Cell Signaling Technology Cat# 2880; RRID: AB_2106495
Phospho-S9-GSK3b Cell Signaling Technology Cat# 9322; RRID: AB_2115196
GSK3bb Cell Signaling Technology Cat# 12456; RRID: AB_2636978
Phospho-T246-PRAS40 Cell Signaling Technology Cat# 2997; RRID: AB_2258110
PRAS40 Cell Signaling Technology Cat# 2691; RRID: AB_2225033
Phospho-T642-AS160 Cell Signaling Technology Cat# 8881; RRID: AB_2651042
AS160 EMD Millipore Cat# 07-741; RRID: AB_492639
Phospho-T389-S6K1 Cell Signaling Technology Cat# 9205; RRID: AB_330944
S6K1 Santa Cruz Biotechnology Cat# sc8418 RRID: AB_628094
Insulin Receptor(IR)b Cell Signaling Technology Cat# 3025; RRID: AB_2280448
ACC Cell Signaling Technology Cat# 3676; RRID: AB_2219397
ACLY Cell Signaling Technology Cat# 4332; RRID: AB_2223744
FASN Cell Signaling Technology Cat# 3180; RRID: AB_2100796
ChREBP Novus Cat# NB400-135; RRID: AB_10002435
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Goat anti-Rabbit IgG (H+L) Cross-
Adsorbed Secondary Antibody, Alexa Fluor
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PE-Cy7-conjugated anti-CD45 eBioscience, Thermo Fisher Scientific Cat# 25-0451-82; RRID: AB_2734986
A700-conjugated anti-CD29 BioLegend Cat# 102218; RRID: AB_493711
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REAGENT or RESOURCE SOURCE IDENTIFIER
A647-conjugated anti-CD34 BioLegend Cat# 119314; RRID: AB_604089
LybA/E-conjugated anti-Sca1 eBioscience, Thermo Fisher Scientific Cat# 45-0242-82; RRID: AB_1210701
Chemicals, Peptides, and Recombinant Proteins
4-hydroxy Tamoxifen (4-OHT) Toronto research chemicals H954729
Rosiglitazone Cayman Chemical 71740
Oil Red O Sigma-Aldrich O0625
Human insulin, regular Novo Nordisk #183302
Insulin Sigma-Aldrich I2643
3-isobutyl-1-methylxanthine (IBMX) Sigma-Aldrich I5879
Dexamethasone Sigma-Aldrich D1756
Osmium tetroxide 2% aqueous solution Polysciences Inc #23311
HCS LipidTOXDeepRedNeutral Lipid Stain Invitrogen H34477
Trichostatin A (TSA) Sigma-Aldrich T1952
BODIPY FL C16 Invitrogen D3821
Propidium iodide Invitrogen P3566
Critical Commercial Assays
Dual-Luciferase Reporter assay system Promega E1910
Free Glycerol Reagent Sigma-Aldrich F6428
NEBNext Ultra Directional RNA Library
Prep Kit for Illumina
New England Biolabs E7760
Seahorse XF Glycolysis stress test kit Agilent Technologies Cat# 103020-100
Seahorse XF Palmitate Oxidation stress test
kit and FAO substrate
Agilent Technologies Cat# 103693-100 Cat# 102720-100
Deposited Data
Raw and analyzed data This study GSE146470
Experimental Models: Cell Lines
Immortalized subcutaneous white
preadipocytes
(Tang et al., 2016) N/A
Primary subcutaneous white preadipocytes This study N/A
Experimental Models: Organisms/Strains
Mouse: Prx1-Cre Jackson Labs 005584
Mouse: Adiponectin-Cre Jackson Labs 028020
Mouse: Rictorfloxed Jackson Labs 020649
Mouse: UBC-creERT2 Jackson Labs 007001
Oligonucleotides
Mouse primers IDT See Table S4
Recombinant DNA
pMSCV-Puro (Akama-Garren et al., 2016) RRID: Addgene_68469
pMSCV-ChREBPa-Puro (Witte et al., 2015) N/A
pMSCV-ChREBPb-Puro (Witte et al., 2015) N/A
pMSCV-HA-PPARg2-Hygro This study N/A
pMSCV-Myc-ACLY-Puro (Calejman et al., 2020) N/A
pMSCV-Myc-ACLY-S455D-Puro (Calejman et al., 2020) N/A
pMSCV-Myc-ACLY-S455E-Puro This study N/A
pMSCV-Myc-ACLY-S455A-Puro (Calejman et al., 2020) N/A
PPRE X3-TK-luc (Kim et al., 1998) RRID: Addgene_1015
pMSCV-HA-AKT1-Hygro (Calejman et al., 2020) N/A
pMSCV-HA-AKT1-S473D-Hygro (Calejman et al., 2020) N/A
(Continued on next page)






Further information and request for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David A.
Guertin (david.guertin@umassmed.edu).
Materials Availability
The plasmids and mice in this study were generated from the materials available in Addgene and Jackson Labs, respectively. Please
contact the Lead Contact for further information.
Data and Code Availability
Unprocessed data from this manuscript have been deposited to Gene Expression Omnibus (GEO; GSE146470).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
Weutilized thewhite preadipocytes residing in stromal vascular fraction (SVF) ofUbc-CreERT2;Rictorfloxedmice for in vitro studies. The
SVFs are isolated by digesting the inguinal WAT in digestion buffer (123 mMNaCl, 5 mMKCl, 1.3 mMCaCl2, 5 mM glucose, 100 mM
HEPES, 1% antibiotics and 4% BSA at pH 7.4 containing 1.5 mg/mL of collagenase A). The isolated cells were cultured directly as
primary cells or immortalized by 3T3 immortalization protocol as previously described to generate cell lines (Tang et al., 2016). Cells
were maintained in 25mM glucose (high-glucose), pyruvate and glutamine-containing DMEM in incubators at 37C and 5%CO2. For
adipocyte differentiation (Zebisch et al., 2012), cells were seeded at medium density and allowed to proliferate to confluence in the
presence of high-glucose DMEM containing 10% FBS and 1% antibiotics (called complete medium). Two days after the cells
reached confluency, cells were induced to differentiate by adding induction media (high-glucose DMEM containing 10% FBS,
1% antibiotics, 100 nM insulin, 2 mg/mL dexamethasone, 0.5mM 3-isobutyl-1-methylxanthine (IBMX) and 1 nM Rosiglitazone) for
2 days and themediumwas replaced with complete medium containing 100 nM insulin for another two days and the cells weremain-
tained in completemedium since then until day 8. Deletion ofRictor in preadipocytes was achieved by treating the cells with one dose
of 4-hydroxytamoxifen (4-OHT, 1 mM) for two constitutive days before induction for early deletion as previous described (Hung et al.,
2014; Tang et al., 2016). The cells were exposed to 4-OHT for only 2 days before differentiation and remained 4-OHT-free thereafter,
which also minimizes the effects of 4-OHT on the cells. For Rictor deletion in differentiating adipocytes (Ad-Rictor-iKO), 4-OHT was
supplemented in culture medium for two constitutive days from D2 to D4 after the differentiation was induced. Control cells received
equivalent volume of ethanol (EtOH) as vehicle-treated controls. SVF isolated from Ubc-CreERT2 mice was treated either by EtOH or
Continued
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pMSCV-HA-AKT1-S473A-Hygro (Calejman et al., 2020) N/A
pMSCV-HA-AKT2-Hygro (Calejman et al., 2020) N/A
pMSCV-HA-AKT2-S474D-Hygro (Calejman et al., 2020) N/A
pSV Sport PPAR gamma 1 Addgene RRID: Addgene_8886
pSV Sport PPAR gamma 2 Addgene RRID: Addgene_8862
Software and Algorithms
ImageJ (Fiji) (Schindelin et al., 2012) https://imagej.nih.gov/ij/
Adiposoft Fiji plugin) (Galarraga et al., 2012) N/A
star_2.5.3a (Dobin et al., 2013) N/A
Ensembl annotation GRCm38.94 (Zerbino et al., 2018) N/A
featureCounts_1.5.2 (Liao, Smyth, and Shi 2014) N/A
DESeq2_1.20.0 (Love, Huber, and Anders 2014) N/A
Other
ChIP-Atlas (Oki et al. 2018) N/A
DAVID Bioinformatics Resources 6.8 (Huang, Sherman, and Lempicki 2009a;
2009b)
https://david.ncifcrf.gov/home.jsp
CytationTM 5 Image reader Biotek N/A
LSRII A-5 laser flow cytometer BD Biosciences N/A
Seahorse XFe96 Analyzer Agilent N/A




4-OHT to address the effect of Cre. At different time points during differentiation, cells were collected for protein, mRNA or Oil-Red-O
staining analysis. To analyze the signaling, cells were serum starved in high-glucose DMEM for 3 hours and stimulated with 100 nM
insulin for 15 minutes.
Mice and Mice Housing
Rictor-floxed mice were described previously (Shiota et al., 2006) and were crossed with mice expressing either Prx1-Cre (JAK
#005584), Adiponectin-Cre (JAK #028020) or Ubc-CreERT2 (JAX #007001) mice to generate conditional or inducible KO models.
Floxed Cre-negative mice were used as controls. All the mice were in C57BL/6 background. The mice used for all studies were be-
tween 8–20weeks old.Micewere housed in the Animal Medicine facilities of the UMMS in a clean room set at 22Cand 45%humidity
under daily 12h light/dark cycles in ventilated racks with cages changed every two weeks, and fed a normal chow diet (Prolab Iso-
pro RMH 3000) from Lab Diet ad libitum. For HFD challenge, diet was switched from normal chow to 60% HFD (D12492 Harlan
Laboratories) when the mice were 8 weeks old. The mice were monitored for 12 weeks and the body weight was recorded weekly.
Both male and female mice were utilized in this study. All animal experiments were approved by Institutional Animal Care and Use
Committee of University (IACUC) of Massachusetts Medical school (UMMS). No animals were excluded from any experiments, un-
less they displayed obvious wounds from fighting as determined by our veterinarians.
METHOD DETAILS
Immunofluorescence and LipidTOX staining
Cells seededoncoverslipswerefixedwith iced-coldmethanol at20C for 15min.Fixedcellswere thenblockedwithPBScontaining3%
BSAand0.3%Triton for 30min at roomtemperature, and incubatedwithprimary anti-perilipin1 (CST, 1:200diluted in1%BSAand0.1%
Triton) at 4Covernight. AfterwashedwithPBS three times, the coverslipswere stainedwith secondary antibodies (AlexaFluor-488-con-
jugated goat anti-rabbit IgG, Invitrogen, 1:400) mixed with HCS LipidTOX deep red neutral lipid stain (Invitrogen, H34477) at room tem-
perature for anhour followedbyDAPIstainingandmountedonglassslideswithProlongGold.Cellswereexaminedwitha laser-scanning
microscope (Zeiss Axio imager). At least 6 images were obtained for each condition and the images were analyzed by ImageJ.
Oil Red O staining
The differentiated cells were washed three times with PBS and fixed with 10% buffered formalin at 4C overnight. Cells were incu-
bated in propylene glycol and then stained with a filtered Oil Red O solution (0.5% Oil Red O in propylene glycol) for 10 min at 37C,
washedwith 85%propylene glycol and three timeswith distilled water, and visualized under amicroscope (Zeiss). Oil RedO contents
were then quantified by direct extraction of Oil Red O from stained cells using isopropanol and absorbance at 510 nM using a micro-
plate reader (Tecan Safire2).
Western blot analysis and immunoprecipitation assays
Cells were harvested in cold PBS and lysed in protein lysis buffer (1% Triton X-100, 50 mM HEPES at pH 7.4, 150 mM NaCl, 5%
glycerol, 2 mM EDTA, protease/phosphatase inhibitor cocktails). For immunoblot analysis of surgically dissected fat tissue depots,
tissues were homogenized and lysed in RIPA buffer (150 mM NaCl, 50 mM HEPES at pH 7.4, 0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 0.5% Na-deoxycholate) containing protease and phosphatase inhibitor cocktails. Protein lysates were mixed with 5X SDS
sample buffer and boiled, separated by SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membrane filters and subjected
to immunoblot analysis. Antibodies used in this study are listed in Key Resources Table. The PPARg antibody was validated by tran-
siently expressing recombinant PPARg1 (with pSV Sport PPAR gamma) 1 or PPARg2 (pSV Sport PPAR gamma 2) in HEK293T cells
andmatching the resulting recombinant protein bands in side-by-side western blots with endogenous PPARg1 andPPARg2, respec-
tively, in primary and differentiated SVF cells.
Gene expression analysis
Total RNA was isolated from cells or tissues using QIAzol (QIAGEN, #79306) and an RNeasy kit (QIAGEN). Equal amounts of RNA
were retro-transcribed to cDNA using a High capacity cDNA reverse transcription kit (#4368813, Applied Biosystems). Quantitative
RT-PCR (qRT-PCR) was performed in 10 mL reactions using a StepOnePlus real-time PCR machine from Applied Biosystems using
SYBR Green PCR master mix (#4309156, Applied Biosystems, or 2XUlrtraSYBR from CWBio) according to manufacturer instruc-
tions. TATA-box binding protein (Tbp) gene expression was used as a normalization gene in all conventional RT-PCR experiments.
Data analysis was performed on web-based software provided by the manufacturer. Primer sequences are shown in Key Resources
Table and Table S4.
RNA-sequencing (RNA-seq) and Bioinformatics analysis
RNAs were extracted from primary culture cells as described. Extracted RNA (3ug) was processed for mRNA isolation using NEB-
Next Poly(A) mRNA Magnetic Isolation Module (NEB, #E7490). Isolated mRNA was used to generate a cDNA library using NEBNext
Ultra II Directional RNA Library Prep Kit for Illumina according to the manufacturer’s instructions. For the multiplex purpose, the
libraries were barcoded using commercially available primers for Illumina system (NEB). The quantity and quality were checked using




Qubit and a fragment analyzer (a service provided byMolecular Biology Core Lab, MCBL at UMMS), respectively. The sequence was
done by paired end read 100 bases using HiSeq 4000. For bioinformatics analysis,
Bioinformatics analysis
With star_2.5.3a (Dobin et al., 2013), paired-end reads were aligned to mouse genomemm10 (GRCm38.p6), which is annotated with
Ensembl annotation GRCm38.94 (Zerbino et al., 2018). Aligned exon fragments with mapping quality higher than 20 were counted
toward gene expression with featureCounts_1.5.2 (Liao et al., 2014). Differential expression (DE) analysis was performed with DE-
Seq2_1.20.0 (Love et al., 2014). Within DE analysis, mouse was taken as a known batch variable. Also, ‘ashr’ was used to create
log2 Fold Change (LFC) shrinkage for each comparison (Stephens, 2017). Significant DE genes (DEGs) were filtered with the criteria
FDR < 0.05 and absolute log2 fold change (|LFC|) > 0.485 (fold change > 1.4). The analyzed data is listed in Table S5. Gene set enrich-
ment analysis was performed using DAVID Bioinformatics Resources online (Huang et al., 2009a, 2009b) and ChIP-atlas for tran-
scription factor interaction (Oki et al., 2018).
Chromatin immunoprecipitation (ChIP) analysis
Nuclei were isolated using nuclei preparation buffer supplemented with protease inhibitor and deacetylase inhibitor (Trichostatin A,
TSA), and nuclei were pelleted by centrifugation. Cells were cross-linked with 1% paraformaldehyde for 10 minutes at room temper-
ature and quenched for 10 minutes by adding 0.125 M glycine. After three washes with cold PBS, cells were lysed with lysis buffer
(1% SDS, 20 mMEDTA pH8, 50 mM Tris-HCl pH8) supplemented with protease inhibitor and deacetylase inhibitor and placed on ice
for 10minutes. Fractionation of chromatin was done by Bioruptor (setting: 2 cycles, 15minutes eachwith high intensity 30-30 s on-off
interval). ChIP was done using the indicated primary antibodies and incubated overnight. Pull down of antibody-bound fragments
was done by adding agarose protein G beads (Prometheus), followed by serial washes two times each with RIPA low salt buffer
(0.1% SDS, 1% Triton x-100, 1 mM EDTA, 2 0mM Tris-HCl pH 8, 140 mM NaCl and 0.1% Na Deoxycholate), RIPA high salt buffer
(0.1%SDS, 1%Triton x-100, 1mMEDTA, 2 0mMTris-HCl pH 8, 500mMNaCl and 0.1%NaDeoxycholate), LiCl buffer (250mMLiCl,
0.5% NP40, 0.5% Na Deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH8) and TE buffer (10mM Tris-HCl pH8 and 1 mM EDTA). DNA
fragments were eluted by 100 mM NaHCO3 and 1% SDS, uncrosslinked, and treated with protease K and RNase. Fragments were
eluted by phenol-chloroform extraction. Eluted fragments were analyzed by RT-PCR using the primers listed in Key Resources Table.
Luciferase Reporter Gene assay
The luciferase reporter containing PPRE (PPRE X3-TK-luc) was a gift from Bruce Spiegelman (Kim et al., 1998). The PPRE-firefly luc-
containing plasmid is transiently co-transfected with RL-TK (containing Renilla-Luc as reference for transfection efficiency) into pre-
adipocytes. Rictor deletion was deleted 24 hours after the transfection and differentiation was done as previously described. At day 2
of differentiation, cells were lysed and enzymic reactions were done using Dual Luciferase reporter Assay (DLR from Promega). The
relative firefly luciferase/Renilla luciferase signals were determined by a microplate reader (Tecan Safire2).
Construction of overexpression by retroviral infection
To generate retroviruses, HEK293T cells were transfected with pMSCV-retroviral vectors subcloned with PPARg2, ChREBPa,
ChREBPb, SREBP1n, ACLY with mutants, and AKT with mutants in combination with the retroviral packaging DNA (pCL-Ampho).
Culture media was changed 12 hours after transfection and the virus-containing supernatant was collected 48 hours after transfec-
tion and passed through a 0.45 mm (PVDF) filter. Preadipocytes were transduced in medium containing 8 mg/mL of polybrene by
centrifugation at 1700 RPM for 30 min. After 24 hours, cells were subjected to antibiotic selection and future analysis. The plasmids
used in this study are listed in Key Resources Table.
Glucose uptake measurement
Cells were preincubated for 3 h in KRH medium without glucose (120 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.3 mM MgSO4, 1.3 mM
KH2PO4 andHEPES 25mMwith pH 7.4 plus 0.5%BSA + 2mMpyruvate). For insulin stimulated group, cells were treatedwith 100 mM
insulin for 15 minutes at the end of incubation. Deoxy-D-glucose 2-[1,2-3H(N)] mixed with unlabeled 2-DOG was then added, and
incubation was continued for an additional 10 min. The medium was then removed and cells were washed three times with KRHme-
dium without glucose and BSA to terminate the assay. Cells were then lysed in 1% triton, mixed with scintillation buffer, and the up-
take of 3H glucose was quantified in counts per minute (cpm) using a scintillation counter. The cpm values were normalized to the
protein concentration of each sample. For in vivo glucose uptake measurement, mice were fasted for 6 hours and were received an
intraperitoneal injection of 10 mCi of Deoxy-D-glucose 2-[1,2-3H(N)] in a total volume of 150 mL. Two hours following the injection,
mice were euthanized and tissue samples were collected, weighed and homogenized. Specific fractional uptakes of 3H-deoxyglu-
cose were determined by scintillation counter.
De novo lipogenesis assay
Cells were incubated with 25 mM DMEM in which 0.01% of the total glucose concentration of the medium was comprised of D-
[U-14C]-glucose for three days. Chloroform extraction was performed, and labeled lipids weremeasured using a scintillation counter.
Each sample was normalized to total protein concentration.




BODIPY FL C16 uptake
BODIPY FLC16, a fluorescence analog of palmitic acid, were utilized formeasuring lipid uptake as previously described (Dubikovskaya
et al., 2014). Primary preadipocytes were cultured and induced into differentiation as previously described. At the end of differentiation,
culturedmediumwas replacedbyHBSSwith 0.1% fatty acid freeBSAcontaining 2 mMBODIPY FLC16 and the cells were incubated for
10minutes or 30 minutes. The reaction was stopped by washing with cold PBSwith 0.2%BSA. Cells were then trypsinized and diluted
with FACS buffer (HBSS with 10% FBS, 10 mM EDTA, 50 mg/mL propidium iodide) and proceeded to FACS analysis (LSRII A-5 Laser).
Glycolytic stress test
Glycolytic ability wasmeasured using a Seahorse XFe96 analyzer (Agilent Technologies). Mouse primary preadipocytes were seeded
in a XFe96 cell culture microplate (Agilent Technologies) and differentiation was induced as previously described. At differentiation
day 8, cells were washed and incubated with assay medium for 1 h at 37C in a CO2-free incubator. Plates were then transferred to a
Seahorse Bioscience XFe96 analyzer. Extracellular acidification rate (ECAR) were measured at baseline, followed by adding 10 mM
glucose, oligomycin (1.5 mM), and 50 mM 2-deoxyglucose. indicates glycolytic capacity. The ECAR was normalized to cell number
determined by CytationTM 5.
Measurement of lipolysis in adipose tissue
For measurement of lipolysis, cultured adipocytes or adipose tissues from mice were harvested and incubated in DMEM with or
without isoproterenol at 10 mM for 4 or 6 hours and the medium were collected to measure glycerol concentration using commercial
kit (Free glycerol reagent, Sigma). The glycerol level was normalized with protein concentration of the tissue mass.
Histone extraction
Cells were washed 2 timeswith PBS and lysedwith Triton extraction buffer (PBS containing 0.5%Triton X-100, protease inhibitor and
1 mM TSA) for 10 minutes at 4C with gentle swirling. Lysates were pelleted and the pellets were resuspended in 0.2N HCl and incu-
bated at 4C overnight. Centrifugation was done in the next day and supernatants were collected for western blots.
Tissue harvest and histology
Adipose tissue depots and other organs/tissues were carefully dissected to avoid contamination from surrounding tissues. Organs/
tissues were weighed by a microscale (XS105, Mettler Toledo). Samples for RNA or protein were frozen down immediately in liquid
nitrogen and stored at 80C for further analysis. For signaling, mice were fasted for 6 hours in the morning without changing other
husbandry conditions. The same amount of normal chow diet was provided for an hour after fasting period and the indicated tissues
were harvested and stored as described above. For histology, tissue pieces were fixed by 10% formalin. Embedding, sectioning and
Hematoxylin & Eosin (H&E) staining were done by the UMass Medical School Morphology Core. Liver samples were embedded in
O.C.T. compound (Tissue-Tek) before sectioning and Oil Red O staining. Images were taken by Zeiss Axio microscope. For cell
size measurements, tissue slices were scanned by Zeiss Axio Scan.Z1 (N = 4 for wild-type and 4 for conditional KOs) and the adipo-
cyte size was automatically measured by ImageJ with plug-in (Adipose). More than 1000 cells were analyzed for each depot. For
estimating adipocyte number in a depot, average adipocyte volume was calculated from more than 800 cells which were imaged
as described above. The adiposity was then determined by depot weight-to-average adipocyte volume ratio.
Glucose Tolerance Test / Insulin Tolerance Test
Animals subjected for glucose tolerance test (GTT) were fasted overnight, followed by intraperitoneal glucose (2 g/kg of body weight)
injection. For insulin tolerance test animals were fasted for 5 hours in the morning without changing other husbandry conditions, fol-
lowed by intraperitoneal insulin (0.75 U/kg of body weight, Novolin) injection. Blood glucose levels were measured by tail bleeding
with a commercially available glucose meter (GE) at indicated time points.
Liver TAG measurement
The protocol is modified from a previously described method (Jouihan, 2012). For each sample, 100-300mg of liver was taken and
lysed in ethanolic KOH (2 parts of ethanol and 1 part of 30% KOH) at 55 overnight. Digested lysates were diluted with 50% EtOH and
centrifuge for 5minutes. 200 uL of lysate were taken andmixed with 215 uL 1MMgCl2, then themixture was left on ice for 10minutes
and followed by centrifugation for 5 minutes. Mixtures were mixed with Free Glycerol Reagent (Sigma) and incubated for 15 minutes
at 37C. The samples were measured by a microplate reader at 540 nm absorbance.
Serology
Blood was collected from animals by cardiocentesis. Serum was collected from the supernatant after centrifugation. The analysis of
insulin, NEFA, leptin and adiponectin was performed by National Mouse Metabolic Phenotyping Center (MMPC) at UMMS.
Marrow fat quantification by osmium staining and CT
The protocol was modified from a previously described method (Scheller et al., 2014). Bones were fixed for 24–48 hours in 10%
neutral-buffered formalin (VWR, Radnor, PA; cat. no. 16004-128), washed with water and decalcified in 14% EDTA, pH 7.4, for




14 days. After washing again with water, 600 ml Sorensen’s phosphate buffer (pH 7.4) was added to one bone (tibia) in a 1.5mLmicro-
tube. Four per cent osmium tetroxide (200 ml) solution (ElectronMicroscopy Services, Hatfield, PA; cat.no. 19170) was added to each
tube to make a 1% solution. Bones were stained in the fume hood 48 hours at room temperature. Osmium solution was carefully
removed to a small liquid waste container that had been filled with corn oil to 25% of the volume. Any used pipet tips were ‘rinsed’
of active osmium tetroxide by pipeting corn oil. All tips and tubes were discarded as osmium solid waste. Bones were washed, in the
same tube, by incubating in 1 ml of Sorensen’s buffer for 3 h at room temperature. This was repeated twice and the last wash was left
in the hood overnight. Stained boneswere thenmoved to a fresh set of 1.5mlmicrotubes containing 1ml Sorensen’s buffer each. The
used tubes were discarded as solid osmiumwaste. At this point, the bones and tubeswere removed from the fume hood and used for
CAT scan.
MicroCT
Specimens were embedded in 1% agarose and placed in a 19-mm diameter tube. The length of the bone was scanned using a mCT
system (mCT100 Scanco Medical, Bassersdorf, Switzerland). Scan settings are as follows: voxel size 12 mm, medium resolution, 70
kVp, 114 mA, 0.5 mm AL filter and integration time 500 ms. Density measurements were calibrated to the manufacturer’s hydroxy-
apatite phantom. Analysis was performed using the manufacturer’s evaluation software and a threshold of 400 for MAT.
APC quantification
APCs were isolated as previously described (Rodeheffer et al., 2008). In brief, stromal-vascular fraction (SVF) was prepared from
SWAT by collagenase (1.5mg/mL) treatment and the pellets were resuspended in erythrocyte lyses buffer (0.15 M NH4Cl and
0.01 M KHCO3 in water). Cells were then pelleted and resuspended in staining media (Hanks’ balanced salt solution (HBSS) with
2% fetal bovine serum) and labeled with the following primary antibodies: PE-Cy7-conjugated anti-CD31, PE-Cy7-conjugated
anti-CD45, A700-conjugated anti-CD29, A647-conjugated anti-CD34 and LybA/E-conjugated anti-Sca1 Antibodies. After staining,
cells were filtered through a 35-mm cell-strainer capped tube (#352235, BD Falcon) to ensure single-cell suspension and stained
with live/dead Blue (L34962, Invitrogen). Live single cells were gated according to the expression of surface markers
(CD31CD45CD29+CD34+Sca1+) in a BD LSRII analyzer. Data were analyzed with FlowJo.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean + SEM, unless stated otherwise. Student’s t test, or non-parametric Mann-Whitney test, were used to
determine statistical significance. Statistical analysis was done using GraphPad Prism. The number of mice used per experiment is
stated in each figure legend.
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